In Brief: Roche Xeloda

Executive Summary

Roche Xeloda: FDA's Oncologic Drugs Advisory Committee will discuss Roche's capecitabine on the afternoon of March 19 for treatment of locally advanced or metastatic breast cancer after failure of paclitaxel and an anthracycline-containing regimen. During the morning session that day, the committee will review a supplement for Lilly's Gemzar (gemcitabine) as a single agent or in combination with cisplatin for first-line treatment of locally advanced or metastatic NSCLC. The meetings begin each day at 8 a.m. at the Bethesda, Md. Holiday Inn...